Metabolon Announces Insulin Resistance Biomarker Poster Presentations at American Diabetes Association Meeting
Analyses of biomarkers provides insight into the identification of patients at high risk of developing type 2 diabetes and fatty liver disease
RESEARCH TRIANGLE PARK, N.C. (June 24, 2011) — Metabolon, Inc., the leader in metabolomics, biomarker discovery and biochemical analysis, announced today that two posters highlighting the Company’s research into insulin resistance biomarkers will be presented at the American Diabetes Association Meeting in San Diego, June 24-28. The posters demonstrate how insulin resistance markers can be utilized in identifying people at high risk for developing type 2 diabetes or fatty liver disease.
The first two posters will be displayed in the ADA designated poster section, will be presented as audio poster tours on Saturday, June 25 from 11:30a.m. -12:30p.m, and will be attended by their presenters on Monday, June 27, from 12:00p.m.-2:00p.m. The third poster was accepted as a Late Breaking ADA abstract and will be attended to on Sunday, June 26 from 12:00p.m.-2:00pm.
“Metabolic Markers of Insulin Sensitivity Predict Progression to IGT and T2D”, will be presented by Walt Gall, Ph.D., Metabolon, Inc.; the study demonstrated that the measurement of a panel of insulin resistance markers in a fasting plasma sample can identify high-risk insulin resistant subjects with high accuracy. This measurement can also predict the progression to impaired glucose tolerance and type 2 diabetes. Abstract # 1512-P.
“Alpha-Hydroxybutyrate and Linoleoyl-Glycerophosphocholine as New Markers of Fatty Liver Disease”, will be presented by Amalia Gastaldelli, Ph.D., CNRS, Pisa, Italy; the study determined that raised plasma concentrations of Alpha-Hydroxybutyrate (a-HB) and Linoleoyl-Glycerophosphocholine(L-GPC), both produced in the liver, mark for the presence of fatty liver disease. Low L-GPC levels were also found to be specifically associated with hepatic insulin resistance. Abstract # 1667-P.
“Metabolite Quantitative Trait Loci (mQTL) and Their Role in Type 2 Diabetes and Insulin Sensitivity,” will be presented by Weijia Xie, University of Exeter, UK; the study determined that a number of metabolites associated with the gold standard measure of insulin sensitivity were associated with diabetes-related loci such as FADS, with a novel GWAS association identified for the top amino acid associated with insulin sensitivity, glycine, having an association with an allele in an aldehyde dehydrogenase, ALDH1L1. These genetic association findings may increase our understanding at the gene level of why certain metabolite levels are abnormal with insulin resistance and development of type 2 diabetes. Abstract # 0073-LB– Late Breaking ADA Abstract.
Commenting on the poster presentations, Metabolon CEO, John Ryals said, “We are excited to share these results at the ADA, the largest gathering of medical professionals in the fight against diabetes. Metabolomics is a very powerful approach to identifying chemical biomarkers, especially biomarkers of disease. The data presented here on insulin resistance, a precursor to type 2 diabetes, which affects an estimated 79 million people in the U.S. alone, moves Metabolon closer to advancing our plans to fulfill the promise of personalized medicine."
Metabolon, Inc. has advanced the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure all of the biochemicals in a biological sample through its proprietary global processing method. Through the generation and interpretation of data, this method provides a precise understanding of disease etiology and drug action, and advances personalized medicine beyond what genomics and other approaches can promise. Metabolon’s expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabalytics, its biomarker discovery and analysis business, has completed over 320 client studies and processed over 30,000 samples for customers in 2010 alone. Building on its expertise in biochemistry understanding, Metabolon is also developing proprietary diagnostic tests to determine and track disease progression. For more information about Metabolon, please visit www.metabolon.com or contact Matt Zaske firstname.lastname@example.org at (919) 595-2200.
Lippert/Heilshorn & Assoc.